Xiaomei Lyu | Genetic Engineering and Biotechnology | Best Researcher Award

Prof. Xiaomei Lyu | Genetic Engineering and Biotechnology | Best Researcher Award

Professor | Jiangnan University | China

Prof. Xiaomei Lyu is a leading researcher in synthetic biology-driven food science, microbial engineering, and biotechnology. Her work focuses on designing programmable microbial systems, metabolic pathway engineering, and CRISPR-based genetic regulation for applications in food functionality, metabolic health, and biomanufacturing. Her research contributions span high-impact areas such as microbial biosensing, host–microbe interaction engineering, and sustainable biosynthesis of value-added compounds. Prof. Xiaomei Lyu has contributed significantly to the development of engineered microbial genetic circuits targeting biomedical and functional-food applications. Her notable advancements include CRISPR-regulated biosensing systems and controllable nanocarriers enabling active delivery of gene-editing components (Small, 2021). She has also pioneered strategies for modularizing and optimizing metabolic pathways in microbial chassis to enhance production efficiency of nutraceutical compounds, as demonstrated in her work on delta-tocotrienol biosynthesis (Journal of Agricultural and Food Chemistry, 2023). Her research on Rhizobium-derived beta-glucan has opened new avenues in microbiota-modulated metabolic regulation. These works revealed mechanisms by which microbial polysaccharides influence triglyceride metabolism, intestinal fat absorption, and gut–host crosstalk, producing valuable implications for obesity and metabolic disorder interventions (Food & Function, 2022; 2024). Additionally, Prof. Xiaomei Lyu has made recognized contributions to enzymatic and chemo-catalytic processes relevant to food biotechnology, including lactulose production and salidroside biosynthesis, helping advance industrial and functional food innovation. Her publication record includes influential papers in Nature Communications, Small, Food & Function, Biotechnology Advances, Phytochemical Reviews, and Journal of Agricultural and Food Chemistry, supported by strong citation performance (Scopus: 1,515 citations, 59 documents, h-index 22). Her scholarly impact extends to R&D in microbial engineering, biochemical pathways, food-derived therapeutics, and microbiome-based metabolic interventions. Prof. Xiaomei Lyu’s research achievements establish her as a prominent contributor to next-generation microbial biotechnology, functional food science, and precision metabolic modulation.

Profiles: Scopus | ResearchGate | Sci Profiles

Featured Publications

1. Gu, B., Zhang, W.-D., Feng, J.-D., Zhao, W., Gu, Z.-G., & Lyu, X. (2025). Upcycling CO₂ into single cell protein via an integrated electrocatalytic–biosynthetic system. ACS Sustainable Chemistry & Engineering. https://doi.org/10.1021/acssuschemeng.5c06506

2. Wang, L., Zeng, Q., Gu, J., Wang, M., Yang, R., & Lyu, X. (2025). High conversion of value-added lactulose from lactose-rich dairy waste by in vivo cascade cell factory. Journal of Agricultural and Food Chemistry. https://doi.org/10.1021/acs.jafc.5c03933

3. Zeng, Q., & Lyu, X. (2025). Identification of a novel cellobiose 2-epimerase from Acidobacteriota bacterium and its application for in-situ milk catalysis. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1575725

4. Liu, H., Zeng, Q., Zhu, C., Xu, C., Yang, R., & Lyu, X. (2025). High-throughput screening and directed evolution of β-1,3-N-acetylglucosaminyltransferase for enhanced LNnT production in engineered Saccharomyces cerevisiae. Journal of Agricultural and Food Chemistry. https://doi.org/10.1021/acs.jafc.5c01311

5. Liu, H., Liu, Y., Hu, H., Zhang, S., Lyu, X., & Yang, R. (2024). De novo production of LNnT by metabolic engineering of Saccharomyces cerevisiae as cell factory. Food Science and Human Wellness. https://doi.org/10.26599/fshw.2024.9250342

Zu-Chian Chiang | Biotechnology | Best Researcher Award

Dr. Zu-Chian Chiang | Biotechnology | Best Researcher Award

Zu-Chian Chiang at Fujian Normal University, China.

Dr. Zu-Chian Chiang is a materials scientist and biomedical researcher specializing in antibody–drug conjugates (ADCs), aptamer-based therapeutics, and functional biomaterials for cancer therapy and regenerative medicine. With a strong foundation in chemical engineering and molecular design, his research spans across Taiwan and China, advancing innovative strategies in translational medicine.

Publication Profile

Scopus

Educational Details

  • Ph.D. in Materials and Chemical Engineering
    National United University, Taiwan | Sept 2008 – Jul 2014

    • Advisor: Prof. An-Chong Chao

    • Co-Advisor: Dr. Guo-Chung Dong, NHRI

  • M.S. in Chemistry
    Tunghai University, Taiwan | Sept 2005 – Aug 2007

    • Advisor: Prof. Feng-Di Lung

Professional Experience

Dr. Chiang has extensive postdoctoral research experience in interdisciplinary biomedical research.

  • Postdoctoral Fellow
    Fujian Normal University, Biomedical Research Center of Southern China (2019–Present)
    Focus: Development of ADCs and aptamers in cancer therapy under Prof. Qi Chen.

  • Postdoctoral Fellow
    Academia Sinica, Institute of Biological Chemistry (2016–2019)
    Participated in the Taiwan Protein Project (TPP) and the TSPA platform, supervised by Academician Hui-Kung Wang.

  • Postdoctoral Fellow
    Clinical Trial Center, National Taiwan University Hospital (2015–2016)
    Selected for the 3rd Biotech Elite Training Reserve Program (MOST). Mentored by Dr. Chih-Hao Chang.

Teaching Experience

  • Served as a Teaching Assistant (2005–2013) in a wide range of chemistry and chemical engineering subjects including Organic Chemistry, Physical Chemistry, Thermodynamics, and Instrumental Analysis at both Tunghai University and National United University.

Research Interest

  • Design and synthesis of functional peptides for cancer therapy and bone tissue regeneration

  • Development of biomicro- and macromolecular composites for regenerative medicine

  • Engineering antibody–drug conjugates (ADCs) for targeted cancer treatment

  • Construction of aptamers as molecular blockers, agonists, or antagonists in oncology applications

Author Metrics

  • Total Publications: 7 peer-reviewed journal articles

  • Total Citations: 93 (as of latest data)

  • h-index: 5

  • Research Interest Score: 49.5 (ResearchGate metric)

Top Noted Publication

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Authors:
Z.C. Chiang (Zu-Chian Chiang), S. Fang (Shubin Fang), Y. Shen (Yangkun Shen), D. Cui, H. Weng, D. Wang, Y. Zhao, J. Lin (Jizhen Lin), Q. Chen (Qi Chen)

Journal:
Frontiers in Oncology
Year: 2022
Volume: 12
Article ID: 857927
DOI: 10.3389/fonc.2022.857927
Access: Article • Open Access
Article Type: Original Research

Author Roles:

  • First Author: Zu-Chian Chiang

  • Co-first Author: Shubin Fang (#)

  • Corresponding Authors: Jizhen Lin*, Qi Chen*

Summary:
This study presents the design and evaluation of novel CD47-targeting antibody–drug conjugates (ADCs) with high antitumor efficacy against non-small cell lung cancer (NSCLC), demonstrating promising therapeutic potential both in vitro and in vivo.

Conclusion

Dr. Zu-Chian Chiang is an emerging talent in the biotechnology research community, with a clear trajectory toward impactful innovation in cancer therapy and regenerative medicine. His demonstrated strengths in antibody–drug conjugates, biomaterials design, and molecular therapeutics showcase both technical expertise and translational vision.